Group 1 - Liftoff Mobile (LFTO.US) has officially filed for an initial public offering (IPO) with the SEC, aiming to raise up to $400 million [1] - For the nine months ending September 30, the company reported revenues of $491.6 million and a net loss of $25.6 million, compared to revenues of $377.1 million and a net loss of $7.4 million in the same period last year, indicating an increase in losses due to business expansion [1] - The core advertising revenue of Liftoff is primarily driven by its proprietary AI predictive model, reaching approximately 1.4 billion active users daily and serving over 1,000 advertisers [1] Group 2 - The IPO is being underwritten by Goldman Sachs, Jefferies Financial Group, and Morgan Stanley, with plans to list on the NASDAQ Global Select Market under the ticker symbol "LFTO" [2] - Blackstone Group acquired a majority stake in Liftoff in 2021, and General Atlantic purchased a minority stake last year, raising the company's valuation to $4.3 billion [1] - Blackstone will retain voting control of the company post-IPO, which is headquartered in Redwood City, California [1]

2026年1月贵金属市场迎来"开门红"，行情火爆程度超出市场预期。截至1月14日，当月仅过半程，现货黄 金累计涨幅已达7%，盘中突破4629.94美元/盎司的历史峰值；现货白银表现更为凌厉，累计涨幅飙升 23%，一度触及86.22美元/盎司的新高，国内市场同步狂欢，沪银主力合约多次触及涨停，沪金合约涨逾 5%，A股贵金属板块个股集体走强，晓程科技、盛达资源等涨幅超8%。这波凌厉涨势再度让"贵金属牛 市"成为市场热议焦点，而背后是政策不确定性、地缘风险与产业需求的多重共振。 2025年全球新能源汽车销量突破1500万辆，AI服务器出货量增长80%，持续推升白银工业需求。而供应端 方面，南美主要产银国秘鲁、智利因罢工、环保政策等问题产量同比下降8%，再生回收比例仅20%难以弥 补缺口，供需失衡成为白银涨幅远超黄金的关键原因。 资金面的持续涌入为涨势提供了动能支撑。全球最大黄金ETF——SPDR Gold Trust最新持仓增加3.43吨至 1074.23吨，尽管全球最大白银ETF持仓小幅减少，但期货市场投机情绪高涨，白银投机者净多头头寸创下 历史新高。国内市场同样呈现资金加速布局态势，华安黄金易ETF规模逼近千亿 ...

最新财报数据显示，摩根大通(JPM.N)第四季度投行业务费用意外下滑，与公司上月给出的预期不符。 "美国经济依然具有韧性。尽管劳动力市场有所放缓，但形势似乎没有进一步恶化。同时， 消费者仍保持支出动力，企业整体状况仍然健康。" 戴蒙表示，这种局面"可能会持续一段时间"。 财报数据显示，摩根大通全年净利润为570亿美元，虽然亮眼，但仍未能打破2024年的纪录，那是美国 银行史上最高的年度盈利。第四季度交易收入达到82.4亿美元，高于市场调查中最高预估，股票与固收 交易均超预期表现。 去年前三季度，最大型银行的贷款规模以金融危机以来最快速度增长，推升净利息收入。摩根大通第四 季度贷款规模环比增长4%，净利息收入同比增长7%。该行在周二的报告中表示，预计2026年净利息收 入将达到约1030亿美元。 摩根大通还重申，今年预计支出约1050亿美元。负责消费者与社区银行业务的玛丽安·莱克（Marianne Lake）上月在行业会议上提前透露这一展望，并表示支出上升的最大驱动力是"与业务量和增长相关的 费用"。 该行周二发布声明称，2025年最后三个月投行业务创收23.5亿美元，同比下降5%。而摩根大通在去年 12月曾预 ...

Market Performance - The Hong Kong stock market saw a significant early rise but narrowed gains in the afternoon, with the Hang Seng Index closing at 26,848.47 points, up 239.99 points, or 0.90% [1] - The total trading volume for the day was 315.2 billion HKD, showing a slight increase compared to the previous day [1] Sector Highlights - Gold stocks continued their upward trend, with China Gold International (HK02099) rising over 7%, Lingbao Gold (HK03330) up nearly 3%, and Zijin Mining (HK01818) and Shandong Gold (HK01787) both increasing over 2% [3] - The Hang Seng Tech Index closed at 5,869.79 points, up 6.59 points, or 0.11% [4] Company News - Citigroup has aggressively raised its short-term outlook for precious metals, predicting gold prices could reach 5,000 USD/oz and silver 100 USD/oz within three months due to escalating geopolitical risks, physical shortages, and uncertainties in Federal Reserve policies [6] - Innovative drug concept stocks performed well, with WuXi AppTec (HK02359) rising over 8% [7] - WuXi AppTec announced an expected annual revenue of 45.456 billion CNY, a year-on-year increase of 15.84%, with adjusted net profit expected to rise by approximately 41.33% to 14.957 billion CNY [9] - Rongchang Biopharmaceutical (HK09995) signed an exclusive licensing agreement with AbbVie for its new dual-target PD-1/VEGF antibody drug RC148, receiving an upfront payment of 650 million USD and potential total payments of up to 5.6 billion USD [11] Market Outlook - Guosen Securities noted that the Hong Kong stock market has not yet fully strengthened, with traditional industries still dominating, and concerns over intensified competition among internet companies affecting market sentiment [13] - The pricing power of Hong Kong stocks is influenced by overseas risk appetite, and the appreciation of the RMB is being offset by profit-taking sentiment [13] - The AH premium index indicates that quality H-shares are preferred over A-shares, with domestic investors favoring leading companies through southbound channels [13]

Core Viewpoint - The Bloomberg industry report indicates that the Chinese technology giants index is expected to experience significant profit growth by 2026, surpassing the "Big Seven" of the US stock market for the first time since 2022, which has garnered considerable market attention [1][5]. Group 1: Market Performance - Asian technology stocks have shown strong performance in 2026, with a key index tracking Asian tech companies rising approximately 6% year-to-date, compared to a mere 2% increase in the Nasdaq 100 index [2]. - A-shares in the technology sector have collectively surged, with sectors like AI applications and semiconductors seeing weekly gains exceeding 10% [1]. - The Hong Kong market also performed well, with the Hong Kong Technology 30 ETF attracting over 450 million yuan in net inflows over five trading days [1]. Group 2: Factors Supporting Growth - Significant advancements in AI technology and applications have been made by Chinese tech companies, with breakthroughs like the DeepSeek-R1 model driving practical applications [2]. - Policy support, including subsidies for semiconductor localization and investments in the integrated circuit industry, has provided a strong foundation for the development of Chinese tech enterprises [3]. - The increase in semiconductor equipment procurement subsidies from 25% to 40% is expected to lower procurement costs significantly, enhancing the competitiveness of domestic chip manufacturers [3]. Group 3: Comparison with US Tech Stocks - US tech stocks face pressures from valuation bubbles and slowing growth, with the average P/E ratio of the "Big Seven" around 30 times, significantly higher than the 14 times for Chinese tech stocks [4]. - Concerns about an "AI bubble" have emerged, with discussions about the sustainability of valuations in the US tech sector intensifying [4][5]. - Chinese tech stocks are driven by domestic technological breakthroughs, policy resonance, and internal market demand, contrasting with US tech stocks that rely on global standards and mature ecosystems [5].

Group 1 - Major banks on Wall Street are set to release their Q4 earnings this week, with increasing competition across all business areas, including investment banking, talent acquisition, and technology investments [2] - Morgan Stanley, JPMorgan Chase, Bank of America, and Citigroup are among the banks reporting earnings, with analysts noting that the competition is the fiercest seen in nearly a decade [2] - Compensation trends indicate a strong year for bonuses, particularly in investment banking, with increases projected to exceed 20% year-over-year [2] Group 2 - The global M&A market showed a 45% year-over-year increase in transaction value, despite a slight decline in the number of deals, indicating a recovery in the sector [4] - Analysts expect this momentum to continue, potentially driving growth in investment banking fees and increasing spending from financial sponsors [4] - The demand for talent is rising as M&A activity increases, with firms investing heavily to retain top talent [4] Group 3 - Credit quality remains stable, but there are concerns about potential issues arising from localized problems in the credit market [5][6] - The recent bankruptcies in the subprime auto loan sector have raised questions about the health of the credit market, although major banks are not expected to face significant risks [5][6] - Goldman Sachs is focusing on its OneGS 3.0 initiative, aimed at enhancing profitability through AI, which is anticipated to be a key topic in the upcoming earnings reports [6] Group 4 - AI has transitioned from experimental phases to becoming a core strategic focus for banks, with executives expected to share more details on AI implementation during earnings calls [7] - The emphasis has shifted from pilot projects to enterprise-level strategies, indicating that AI is now a priority for top banks [7]

更多香港上市、美国上市等境外IPO资讯可供搜索、查阅，敬请浏览: www.ryanbencapital.com 彭博社引述消息报道，传闻小鹏汽车(09868.HK)旗下飞行汽车公司小鹏汇天已聘请摩根大通、摩根士丹利，负责安排香港IPO事宜。 小鹏汇天已通过保密方式在港交所提交上市申请，最快可能在今年进行交易。 小鹏汇天，历经数轮融资，其投资者包括IDG资本、五源资本、红杉中国、钟鼎资本、GGV纪源资本、高瓴创投、云锋基金等。 彭博社引述消息报道，传闻小鹏汽车(09868.HK)旗下飞行汽车公司小鹏汇天已聘请摩根大通、摩根士丹利，负责安排香港IPO事宜。 小鹏汇天已通过保密方式在港交所提交上市申请，最快可能在今年进行交易。 小鹏汇天，历经数轮融资，其投资者包括IDG资本、五源资本、红杉中国、钟鼎资本、GGV纪源资本、高瓴创投、云锋基金等。 版权声明：所有瑞恩资本Ryanben Capital的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则瑞恩将向其追究法律责任。部分文 章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。 更多香港上市、美国上市等境外IPO资讯可 ...

Core Dynamics and Data - Historical Breakthrough: On December 23, 2025, COMEX gold futures first broke $4500/oz, reaching a peak of $4555.1; London spot gold also surged to $4525.83/oz, with a year-to-date increase exceeding 70%, marking the largest annual gain since 1979 [2] - Consumer Transmission: Major brands like Chow Tai Fook and Chow Sang Sang saw a daily increase of 36 yuan in gold jewelry prices, with a reported price of 1411 yuan/gram on December 24, totaling a two-day increase of 44 yuan. The cost of 60 grams of wedding "three golds" skyrocketed from under 40,000 yuan at the beginning of the year to over 80,000 yuan, leading some couples to consider rentals or "gold-plated silver" alternatives [2] Driving Forces Behind the Surge - Monetary Easing Expectations: The Federal Reserve is expected to cut rates by 75 basis points cumulatively in 2025, with the market betting on further cuts in 2026. The decline in U.S. Treasury yields diminishes the dollar's attractiveness, while lower real interest rates reduce the cost of holding gold [3] - Surge in Safe-Haven Demand: - Geopolitical Risks: U.S. sanctions on Venezuelan oil tankers and tensions in the Middle East have heightened risk aversion [4] - De-dollarization: Central banks globally purchased a net 634 tons of gold in the first three quarters, with China increasing its gold reserves for 13 consecutive months, leading to a decrease in the dollar's share of foreign exchange reserves to 56.32% [4] - Technical Buying Pressure: The gold price broke through the resistance level of $4380 set in October, triggering algorithmic trading, with gold ETFs experiencing net inflows for five consecutive weeks [4] Market Divergence and Risk Alerts - Bullish Camp: Central bank gold purchases and an ongoing rate-cut cycle support a bullish outlook, with Goldman Sachs predicting $4900 and JPMorgan forecasting $5055 [5] - Cautious Camp: Concerns over short-term overbought conditions and policy fluctuations, with Citigroup warning of a pullback to $4280-$4300 and economist Guan Qingyou cautioning that rapid price increases may not be beneficial [5] - Historical Lessons: In October, gold prices twice touched $4380 before experiencing a single-day drop of nearly $200 (a 6.3% decline), with the current RSI indicating overbought conditions in the 74-80 range [5] Practical Advice for Ordinary Users - Consumer Pitfalls: - Wedding essentials should prioritize gold jewelry priced by weight in markets like Shenzhen's Shui Bei, avoiding brand premiums of around 30% [6] - Consider refurbishing old gold or opting for "gold-plated silver" alternatives, which are priced at only one-fifth of solid gold [6] - Investment Allocation: - Tools: Gold ETFs (with fees <0.5%) and bank gold savings should be preferred, avoiding high-leverage futures due to frequent liquidations at 80x leverage in October [7] - Strategy: Maintain positions at ≤10% of liquid assets, employing dollar-cost averaging to mitigate high-price risks and avoid chasing prices [7] Future Trend Core Contradictions - Upward Momentum: The erosion of the dollar's credit system is transforming gold from an "anti-inflation tool" to the "ultimate asset against sovereign credit risk," with Morgan Stanley predicting gold prices could challenge $7000-$8000 by 2030 [8] - Downward Risks: If the Federal Reserve's independence is restored or if global economic recovery exceeds expectations, a prolonged bear market for gold similar to the 1980-2000 period could re-emerge [8]

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. (ARWR.US) is projected to be one of the best-performing stocks in the U.S. market by 2025, with a cumulative increase of 253%, significantly outperforming major competitors like NVIDIA (NVDA.US) and Micron (MU.US) [1][2] Group 1: Company Overview - Arrowhead Pharmaceuticals is a biotechnology company based in Pasadena, California, focusing on developing therapies for major diseases using RNA interference (RNAi) technology [3] - The company has transitioned from being a clinical-stage biotech firm to a commercialized entity with the approval of its first drug, Redemplo, marking a significant milestone in its development [5][6] Group 2: Product Details - Redemplo is an innovative RNAi-based drug approved by the FDA for treating familial chylomicronemia syndrome (FCS), representing a first-in-class therapy in its category [4][5] - The drug targets the APOC3 gene to significantly lower triglyceride levels in patients, addressing a rare genetic metabolic disorder [4] Group 3: Market Potential and Financial Projections - Piper Sandler has set a bullish target price of $100 for Arrowhead Pharmaceuticals, indicating a potential short- to mid-term upside of 55% from its current price of $64.56 [1][2] - Sales projections for Redemplo in the U.S. market are expected to reach at least $625,000 by Q4 2025, with significant growth anticipated to approximately $12.3 million by 2026 [6] - Morgan Stanley has also raised its target price for Arrowhead from $48 to $81, highlighting the potential for Redemplo to generate over $2 billion in peak global sales if successfully commercialized in broader lipid disorders [7]

Core Viewpoint - Arrowhead Pharmaceuticals, Inc. has shown a remarkable stock performance with a cumulative increase of 253% in 2025, outperforming major players like Nvidia and Micron Technology, indicating strong market interest and potential growth in the biotech sector [1] Group 1: Company Overview - Arrowhead Pharmaceuticals is a California-based biotech company focused on developing therapies using RNA interference (RNAi) technology to treat various serious diseases, including cardiovascular and metabolic diseases, liver diseases, and viral diseases [2] - The company has transitioned from being primarily a clinical-stage biotech firm to a commercial-stage entity with the approval of its first drug, Redemplo, marking a significant milestone in its development [2][4] Group 2: Product Development - Redemplo is a novel RNAi-based drug that has received FDA approval for treating adult familial chylomicronemia syndrome (FCS), representing a first-in-class therapy in its category [3] - The drug targets the APOC3 gene to significantly lower triglyceride levels in the blood, addressing a rare genetic metabolic disorder [3] Group 3: Market Potential and Financial Projections - Piper Sandler has set a bullish target price of $100 for Arrowhead Pharmaceuticals, reflecting a potential upside of 55% from its current stock price of $64.56, indicating strong investor confidence [1] - The expected sales for Redemplo in the U.S. market are projected to reach at least $625,000 in Q4 2025, with significant growth anticipated to approximately $12.3 million in 2026 [4][5] - If Redemplo successfully commercializes in broader lipid disorders, its global peak sales could exceed $2 billion, showcasing substantial revenue potential beyond just FCS [6]